These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 37114853

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Epilepsy with generalized tonic-clonic seizures alone: Electroclinical features and prognostic patterns.
    Cerulli Irelli E, Gesche J, Schlabitz S, Fortunato F, Catania C, Morano A, Labate A, Vorderwülbecke BJ, Gambardella A, Baykan B, Holtkamp M, Di Bonaventura C, Beier CP.
    Epilepsia; 2024 Jan; 65(1):84-94. PubMed ID: 37872695
    [Abstract] [Full Text] [Related]

  • 25. Assessment of the long-term efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of open-label extension studies.
    Piña-Garza JE, Villanueva V, Rosenfeld W, Yoshinaga H, Patten A, Malhotra M.
    Epilepsy Behav; 2022 Oct; 135():108901. PubMed ID: 36122531
    [Abstract] [Full Text] [Related]

  • 26. Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: Analysis of four open-label extension studies.
    Rektor I, Krauss GL, Inoue Y, Kaneko S, Williams B, Patten A, Malhotra M, Laurenza A, Wechsler RT.
    Epilepsia; 2020 Jul; 61(7):1491-1502. PubMed ID: 32645213
    [Abstract] [Full Text] [Related]

  • 27. Perampanel for Treatment of People with a Range of Epilepsy Aetiologies in Clinical Practice: Evidence from the PERMIT Extension Study.
    Strzelczyk A, Maschio M, Pensel MC, Coppola A, Takahashi S, Izumoto S, Trinka E, Cappucci S, Sainz-Fuertes R, Villanueva V.
    Neurol Ther; 2024 Jun; 13(3):825-855. PubMed ID: 38678505
    [Abstract] [Full Text] [Related]

  • 28. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307.
    Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Clément JF, Wang X, Bagul M, Gee M, Zhu J, Squillacote D.
    Epilepsia; 2014 Jul; 55(7):1058-68. PubMed ID: 24867391
    [Abstract] [Full Text] [Related]

  • 29. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.
    Villanueva V, Garcés M, López-González FJ, Rodriguez-Osorio X, Toledo M, Salas-Puig J, González-Cuevas M, Campos D, Serratosa JM, González-Giráldez B, Mauri JA, Camacho JL, Suller A, Carreño M, Gómez JB, Montoya J, Rodríguez-Uranga J, Saiz-Diaz R, González-de la Aleja J, Castillo A, López-Trigo J, Poza JJ, Flores J, Querol R, Ojeda J, Giner P, Molins A, Esteve P, Baiges JJ.
    Epilepsy Res; 2016 Oct; 126():201-10. PubMed ID: 27521586
    [Abstract] [Full Text] [Related]

  • 30. Efficacy, safety, and tolerability of perampanel in Asian and non-Asian patients with epilepsy.
    Tsai JJ, Ikeda A, Hong SB, Likasitwattanakul S, Dash A.
    Epilepsia; 2019 Mar; 60 Suppl 1():37-46. PubMed ID: 30869165
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics.
    Lin KL, Lin JJ, Chou ML, Hung PC, Hsieh MY, Chou IJ, Lim SN, Wu T, Wang HS.
    Epilepsy Behav; 2018 Aug; 85():188-194. PubMed ID: 30032806
    [Abstract] [Full Text] [Related]

  • 32. The real-world effectiveness and safety of perampanel in Europe: A scoping review.
    Estévez-María JC, Garamendi-Ruiz I.
    Epilepsy Behav; 2022 Sep; 134():108777. PubMed ID: 35816832
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs.
    Santamarina E, Bertol V, Garayoa V, García-Gomara MJ, Garamendi-Ruiz I, Giner P, Aranzábal I, Piera A, Arcos C, Esteve P, Marinas A, García-Escrivá A, Viloria-Alebesque A, Loro FA, de Tienda AP, Olivan JA, Bonet M, Dávila-González P, Sivera R, Molins A, Sansa G, Roche JC, Martínez AB, Monteagudo S, Casadevall T.
    Seizure; 2020 Dec; 83():48-56. PubMed ID: 33096456
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
    Krauss GL, Perucca E, Kwan P, Ben-Menachem E, Wang XF, Shih JJ, Patten A, Yang H, Williams B, Laurenza A.
    Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Perampanel in real-world clinical care of patients with epilepsy: Interim analysis of a phase IV study.
    Wheless J, Wechsler RT, Lancman M, Aboumatar S, Patten A, Malhotra M.
    Epilepsia Open; 2021 Mar; 6(1):79-89. PubMed ID: 33681651
    [Abstract] [Full Text] [Related]

  • 38. Idiopathic generalized epilepsies: Which seizure type is more difficult to control?
    Asadi-Pooya AA, Farazdaghi M.
    J Clin Neurosci; 2023 Aug; 114():93-96. PubMed ID: 37348286
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.